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feeding behavior. In this regard, a number of peptides have been shown to be efficiently processed in vitro, including glucagon family peptides, neuropeptides, and chemokines.
In order to better understand the biological role of DP-IV, and to determine the potential therapeutic benefit and safety issues that may be associated with DP-IV inhibition, a thorough understanding of endogenous substrate specificity is required.
Numerous strategies have been devised to determine protease substrate specificity and provide insight into their biological roles. For serine-and cysteine-type proteases, "positional scanning" combinatorial libraries of peptide substrates are often effective in identifying residue specificities proximal to the scissile amide bond and revealing consensus amino acid sequences for substrate recognition (16, 17) . These data can facilitate the identification of potential substrates from protein sequence databases, although rapid assays to quantitatively measure cleavage efficiencies have been lacking to date.
We have been evaluating mass spectrometry (MS) as the method of choice for developing sensitive and quantitative assays of protease activity. MS techniques such as matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOFMS) (18, 19) and electrospray ionization-liquid chromatography/mass spectrometry (ESI-LC/MS) (20) can facilitate quantitative measurements of polypeptide cleavage based upon the specific changes in m/z that accompany each proteolytic event (21) . MS is of particular utility in assays of amino/carboxypeptidase or dipeptidase activity involving the cleavage of only one or two residues, where the quantitation of substrate and product peptides can be limited by the poor resolution and low sensitivity of by guest on September 1, 2017 http://www.jbc.org/ Downloaded from conventional separation techniques such as high performance liquid chromatography and gel electrophoresis. Here, we describe a general MS-based approach for screening libraries of bioactive polypeptides against a target protease, measuring specificity constants of cleavage (k cat /K M ) from a single kinetic run, and evaluating the effects of genetic ablation (or inhibition) of protease activity on the in vivo metabolism of exogenously administered candidate substrates in mice. These studies have led to the identification of oxyntomodulin and growth hormone as novel in vitro substrates for DP-IV, and provide compelling evidence that PACAP38 is regulated by this enzyme in vivo.
EXPERIMENTAL PROCEDURES
DP-IV assay. The panel of 15 hormones and neuropeptides (purchased from Anaspec, Synpep, Bachem, and American Peptide Company) was assayed for DP-IV processing in groups of 5-6 peptides each. A validated physiological DP-IV substrate (GLP-1 [7-36]) was included in each assay as a positive control. Peptide mixtures were compiled so as to avoid any overlap in the mass spectra of prominent charge states for all species present (including potential products of DP-IV-mediated cleavage). A charge state conflict analysis algorithm was implemented using combinatorial optimization to automate the grouping of peptides in each assay, while preventing overlaps in their mass spectra with respect to a minimally acceptable mass/charge separation (typically 6 m/z). Equimolar mixtures containing 250 nM of each peptide in assay buffer (100 mM HEPES, pH 7.5, 0.05 mg/mL BSA) were incubated at 37 °C with soluble recombinant human DP-IV (500 pM, corresponding to 0.96 mU) in a volume of 2 mL (one unit of enzyme activity is 6 defined as the amount of enzyme required to hydrolyze 1 µmol/min of 50 µM Gly-Pro-AMC in 100 mM HEPES buffer containing 0.1 mg/mL BSA, pH 7.5, 37 °C). The kinetic parameters for substrate cleavage by the recombinant enzyme (comprising residues 29-766) were indistinguishable from those of wild type DP-IV. At appropriate intervals (0-120 min after the addition of enzyme), 150 µL aliquots were withdrawn and quenched with 2 µL of 6N HCl. A 90 µL volume of each quenched aliquot was analyzed by ESI-LC/MS, and kinetic progress curves for each processed peptide were obtained as picomoles of each substrate and 20-80 picomoles of the corresponding DP-IV product in 100 µL of assay buffer were prepared using a grouping of peptides identical to that of the in vitro screen. Aliquots of these mixtures (90 µL) were analyzed by ESI-LC/MS. The m/z of predominant charge states for each substrate and product peptide (Table 1 ) was used to generate extracted ion chromatograms from which integrated peak areas were measured. The ratio of the product:substrate peak areas was plotted against the known ratio of product:substrate in the mixtures (Fig. 2) . The slope of the resulting linear plot was used as a response factor to correct the measured peak area of product peptide in the kinetic assays ( slope 8 Calculation of specificity constants. Progress curves for the cleavage of individual substrates (see Fig. 3 ) were generated from extracted ion chromatograms using peak areas of substrate and product, 100 % . .
. For data obtained from repeat assays, the standard error of this measurement was typically < 15% of the mean. The specificity constant (k cat /K M ) for cleavage of a particular substrate was directly calculated from a first order fit of the enzyme kinetics:
, where k obs is the first order rate constant and E o is the total enzyme concentration (22) .
In vivo metabolism of PACAP38. Recoveries of PACAP and PACAP were typically 65% and 78%, respectively. Dried samples were reconstituted in 190 µL of an aqueous solution containing 5% acetonitrile, 5% 1-propanol, and 0.03% TFA. The samples were transferred to 0.5 ml microcentrifuge tubes and centrifuged at 13000 rpm for 5 min.
Supernatants (180 µL) were transferred to plastic LC vials, and 45 µL aliquots were analyzed in triplicate by tandem mass spectrometry. +3 ) with 30% relative collision energy. The total integrated peak area for these major fragment ions was used to quantitate the corresponding peptides, using standard curves generated from plasma samples of known peptide concentrations (Fig. 5 ).
Quantitation of peptides by
The standard error for repeat measurements was <15 % of the mean.
RESULTS AND DISCUSSION
A multiplexed MS-based kinetic assay for proteases. Endogenous levels of circulating bioactive peptides are generally 3-6 orders of magnitude lower than the micromolar K M values for substrates of typical proteases. At such low concentrations, the rate of proteolysis is determined by the specificity constant (k cat /K M ), which represents the apparent second order rate constant for substrate cleavage. Measurement of this kinetic parameter allows substrates to be ranked in order of processing efficiency, with k cat /K M > 10 5 M -1 s -1 being characteristic of efficient cleavage by a particular protease. The in vitro substrate specificity of DP-IV for glucagon family peptides was determined using a mass spectrometry assay that provided a direct measurement of the specificity constant for each substrate. This approach was used to rapidly identify candidate DP-IV substrates for subsequent in vivo analysis. Although MS-based assays of DP-IV activity have been previously reported (23, 24) , our approach quantitatively measures k cat /K M for multiple substrates in a single kinetic experiment. For the glucagon family peptides described in this work, mixtures of 5-6 peptides were assayed simultaneously, allowing automated LC/MS analysis of all 16 peptides to be completed in 36 h. The increased throughput of this method compared to standard HPLC-based assays is further illustrated by our subsequent screen of a library of ~150 neuropeptides, hormones, and chemokines, and measurement of k cat /K M for all identified in vitro DP-IV substrates, which was completed in less than a week.
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Measurement of specificity constants by MS. Since mass spectrometry measures analyte concentrations indirectly, appropriate precautions were taken to ensure that the measured ion signals reflected accurate estimates of substrate turnover. These steps included the measurement of instrument response factors for each substrate-product pair ( Fig. 2 and Table 1 ), and operation within the linear dynamic range of the assay (0-10,000 ng/mL).
The high sensitivity of ESI-LC/MS allowed kinetic data to be collected at relatively low (nanomolar) concentrations of substrate compared to the Michaelis constant (K M ), which is typically in the high-micromolar range for peptides that are cleaved by DP-IV in vitro (14, (25) (26) (27) . Each potential substrate could therefore effectively compete for the enzyme active site without a bias towards high affinity substrates. Under these conditions of low substrate concentrations ([S]< 0.1 K M ), the specificity constant for cleavage could be directly calculated from a single progress curve for each substrate (Fig. 3 ) using the integrated Michaelis Menten equation (22) . Repeat analyses confirmed that kinetic measurements were unaffected by the composition of peptides in the assay mixture.
Identical results were also obtained when substrates were incubated individually with the peptidase.
Efficient in vitro cleavage of P1-Pro/Ala-containing peptides. Table 1 which was further cleaved to GRP as has been previously reported (25, 27) . Rate constants for these cleavages were determined from the progress curves for each species using standard equations (30) . In addition, oxyntomodulin, a glucagon family peptide that inhibits food intake when administered centrally in rats (31), and the pituitary growth hormone fragment GH , which exhibits insulin potentiating activity in obese or diabetic rodents (32, 33) , were established as novel in vitro substrates of DP-IV.
Differential processing of P1-Ser-containing peptides in vitro.
In general, where comparisons can be made, the specificity constants determined in this study are in good agreement with values previously reported in the literature. The exceptions in this regard are data for the P1-Ser-containing peptides glucagon, PACAP27, and PACAP38. The specificity constant determined for glucagon was 10-fold lower than that reported using MALDI-TOF mass spectrometry (34 led to a 400-fold decrease in k cat /K M (26) , and first order rate constants for DP-IV cleavage of Ser-containing GHRH analogs were typically 25-fold lower than that of the corresponding P1-Ala substrates (35). Unexpectedly, PACAP38 and oxyntomodulin, both of which contain basic carboxy-terminal extensions relative to PACAP27 and glucagon, respectively, were processed 15-fold and 8-fold more efficiently than their shorter isoforms in each case. Such differential processing indicates that residues remote from the scissile bond can modulate the efficiency of DP-IV cleavage, as was further demonstrated by a modest (1.5-fold) increase in k cat /K M for GHRH cleavage relative to GHRH .
Differential in vitro processing of the pancreatic neuropeptides PACAP38 and PACAP27 by DP-IV has been previously described (27) . The reported specificity constants of these peptides, however, were an order of magnitude lower than the values obtained in this work. While the reason for these discrepancies is unknown, the evidence linking PACAP to metabolic control (38) , and the requirement of an intact amino-terminus for PACAP bioactivity (36, 37) prompted us to investigate the potential role of DP-IV in the in vivo catabolism of PACAP38.
In vivo metabolism of PACAP peptides monitored by tandem mass spectrometry.
Increased steady-state levels of PACAP38 in DP-IV-deficient mice would provide conclusive evidence of a physiological role for DP-IV in the regulation of this neuropeptide. Unfortunately, measurements of endogenous PACAP38 in mice were not possible for several reasons. First, specific immunoassays that discriminate between intact PACAP and its DP-IV metabolite PACAP were not available. Second, since PACAP38 functions as a non-cholinergic sympathoadrenal neurotransmitter (38) , local stabilization of the neuropeptide at nerve ganglia in DP-IV -/-mice would probably not be reflected in assays that measured circulating peptide. Finally, PACAP38 binds the plasma protein ceruloplasmin (39) , which further complicates the quantitation of endogenous peptide, estimated to be ~25-100 pM (40) . For a typical 100 µL mouse plasma sample, this low abundance of endogenous PACAP38 would require attomole sensitivity of detection, which is approximately three orders of magnitude lower than what can be typically achieved for extracted plasma peptides using conventional ion trap mass spectrometers. We therefore adopted an alternate approach that compared the metabolic fates of exogenously administered PACAP38 in wild type and DP-IV-deficient C57Bl/6 mice. Measurement of intact PACAP and the inactive DP-IV metabolite PACAP in mouse plasma was accomplished using tandem mass spectrometry (MS-MS), following i.v. dosing of animals with supraphysiological levels of neuropeptide.
Although the concentration of infused peptide was much higher than that of endogenous PACAP38, the metabolic fate of this neuropeptide when exposed to a milleu of competing peptidases in vivo (including DP-IV) would still be expected to provide valuable insight regarding the enzyme(s) responsible for its regulation. Indeed, similar infusion experiments using radioiodinated GLP-1 and GIP in DP-IV-positive and -negative rats provided amongst the first in vivo evidence for inactivation of these incretins by the enzyme (3).
The enhanced selectivity and improved sensitivity of tandem mass spectrometry is ideal for the quantitation of peptides in biological samples, where the complexity of the matrix otherwise results in unacceptable chemical noise. The MS-MS experiments for PACAP and PACAP monitored the production of characteristic fragment ions from a specific parent ion following collision-activated dissociation (Fig. 4) .
Despite the high abundance of ceruloplasmin in plasma (1.7 µM, (39)), an ESI-LC/MS-MS assay was developed that simultaneously measures PACAP and PACAP with a limit of quantitation (LOQ) of ~45 nM (200 ng/mL, Fig. 5 ), . The sensitivity and dynamic range of this assay confirmed that the protocols developed for sample preparation were effective in separating PACAP38 from bound proteins, and allowed the metabolism of infused PACAP38 in C57Bl/6 mice to be monitored over a period of several minutes.
PACAP38 but not PACAP27 is processed in vivo by DP-IV.
As illustrated in Fig.6 , exogenous PACAP38 was rapidly degraded in wild type C57Bl/6 mice, with concomitant formation of the inactive DP-IV metabolite PACAP , consistent with our in vitro observations. In contrast, formation of PACAP was virtually absent in age-and gender-matched DP-IV -/-mice, and clearance of intact PACAP38 from the circulation was significantly slower in these animals (presumably by renal filtration, as has been reported for GLP-1 (41)). Significantly, the total concentration of PACAP38 and its DP-IV metabolite in wild type mice was similar to levels of intact PACAP38 in DP-IV -/-animals at each time point (Fig. 6 ), consistent with DP-IV playing a major role in the degradation of circulating PACAP38. A similar experiment monitoring the catabolism of exogenous PACAP27 in wild type C57Bl/6 mice found no evidence of the corresponding des-dipeptidyl PACAP metabolite (data not shown), consistent with the ~15-fold lower specificity constant of this peptide relative to PACAP38. Nevertheless, since PACAP38 constitutes ~90% of the endogenous PACAP pool, metabolic inactivation by DP-IV would be expected to regulate overall PACAP bioactivity in vivo.
The metabolic effects of DP-IV inhibition may involve stabilization of multiple substrates.
Improvements in metabolic control obtained upon inhibition of DP-IV in human subjects and diabetic animals have been classically attributed to stabilization of the incretins GLP- Clearly, additional studies of substrate specificity will also be required to obtain an intimate understanding of the overall biological role of DP-IV, and the prospects and liabilities of enzyme inhibition. human DP-IV and assayed for cleavage by ESI/LC-MS. Kinetic progress curves were generated using peak areas of substrate and product ions that were normalized for differences in ionization efficiencies using previously determined response factors as described under "Experimental Procedures." Specificity constants were determined from first-order fits to the kinetic data using the for six of the eleven peptide species present in the assay (GHRH , GLP-1 , PACAP , and their corresponding des-dipeptidyl DP-IV metabolites)
are also shown. Fig. 2 . Measurement of instrument response factors for GHRH , PACAP38, GLP-1 , and their DP-IV metabolites. The ratio of product:substrate (P/S) determined by mass spectrometry for each peptide is plotted against the actual ratio present in a series of standard mixtures, and the slope of the plot is used as a correction factor in the kinetic assays (see Experimental Procedures). Fig. 3 . Typical kinetic progress curves for DP-IV substrates, generated using the multiplexed MS-based assay. Equimolar mixtures of 5-6 glucagon family peptides were incubated with enzyme, and aliquots sampled by LC/MS at appropriate intervals. The extent of cleavage for each peptide was calculated by ratiometric analysis of the corresponding product-and substrate-ions. The data followed first-order kinetics, and k cat /K M was calculated from the observed rate constant as described under Experimental Procedures. Product ion spectra for PACAP38 (PACAP , precursor ion at m/z 1134.6) and the corresponding DP-IV metabolite PACAP (precursor ion at m/z 1437.7).
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